Effects of deferoximine on chondrocyte alkaline phosphatase activity: Proxidant role of deferoximine in thalassemia

M. Hatori, J. Sparkman, Cristina Teixeira, M. Grynpas, Jeanne Nervina, N. Olivieri, I. M. Shapiro

Research output: Contribution to journalArticle

Abstract

The homozygous form of β-thalassemia, the most common single gene disorder, is treated by red cell transfusion therapy. Following transfusion, the chelator, deferoximine, is administered to patients to remove excess iron. However, when this drug is given to young children, metaphyseal dysplasia and abnormalities of linear growth are frequently observed. To explore the notion that deferoximine mine interferes with endochondral growth by chelating zinc, we examined the effect of the drug on chondrocytes maintained in long-term culture. We found that deferoximine caused a dose-dependent inhibition of a wide range of functions including cell proliferation, protein synthesis (and possibly under-hydroxylation of type X collagen), and mineral deposition. Directly relevant to the mineralization process was the observation that the drug dramatically lowered the activity of alkaline phosphatase, a zinc-requiring enzyme. To test the hypothesis that enzyme inhibition was due to chelation of zinc by deferoximine, the cell culture medium was supplemented with excess zinc. However, this treatment did not overcome the deferoximine-dependent change in enzyme activity. We next examined the possibility that deferoximine, in the presence of ascorbate, could form a free radical system that would serve to inactivate the enzyme. Using alkaline phosphatase extracted from chick cartilage, we noted that the activity of the phosphatase was markedly reduced in the presence of deferoximine and ascorbate. These effects were consistant with the notion that deferoximine and ascorbate can act as a prooxidant couple. This conclusion was confirmed when we measured the oxidative activities of the system using nitroblue tetrazolium and cytochrome c. Indeed, we noted that deferoximine markedly activates the autocatalytic oxidation of ascorbate. We next investigated the possibility that the change in alkaline phosphatase activity was due to the formation of reactive oxygen radicals. Though oxygen radical scavengers and disproportionating agents did not change the activity of the enzyme, α-tocopherol provided complete protection. In conclusion, the deferoximine-ascorbate couple inactivates chondrocyte alkaline phosphatase probably by generation of free radicals. As free radicals can damage cartilage as well as other tissues, clinical regimens that are directed at elevating ascorbate levels in thalassemia need to be carefully reviewed.

Original languageEnglish (US)
Pages (from-to)229-236
Number of pages8
JournalCalcified Tissue International
Volume57
Issue number3
DOIs
StatePublished - Sep 1995

Fingerprint

Deferoxamine
Thalassemia
Chondrocytes
Alkaline Phosphatase
Zinc
Free Radicals
Enzymes
Cartilage
Reactive Oxygen Species
Collagen Type X
Pharmaceutical Preparations
Nitroblue Tetrazolium
Tocopherols
Hydroxylation
Chelating Agents
Growth
Cell- and Tissue-Based Therapy
Cytochromes c
Phosphoric Monoester Hydrolases
Minerals

Keywords

  • Alkaline phosphatase
  • Ascorbate
  • Chondrocytes
  • Deferoximine
  • Free radicals
  • Mineralization
  • Thalassemia

ASJC Scopus subject areas

  • Endocrinology

Cite this

Effects of deferoximine on chondrocyte alkaline phosphatase activity : Proxidant role of deferoximine in thalassemia. / Hatori, M.; Sparkman, J.; Teixeira, Cristina; Grynpas, M.; Nervina, Jeanne; Olivieri, N.; Shapiro, I. M.

In: Calcified Tissue International, Vol. 57, No. 3, 09.1995, p. 229-236.

Research output: Contribution to journalArticle

Hatori, M. ; Sparkman, J. ; Teixeira, Cristina ; Grynpas, M. ; Nervina, Jeanne ; Olivieri, N. ; Shapiro, I. M. / Effects of deferoximine on chondrocyte alkaline phosphatase activity : Proxidant role of deferoximine in thalassemia. In: Calcified Tissue International. 1995 ; Vol. 57, No. 3. pp. 229-236.
@article{f4bd9d436b2245c39712e96d4d508d67,
title = "Effects of deferoximine on chondrocyte alkaline phosphatase activity: Proxidant role of deferoximine in thalassemia",
abstract = "The homozygous form of β-thalassemia, the most common single gene disorder, is treated by red cell transfusion therapy. Following transfusion, the chelator, deferoximine, is administered to patients to remove excess iron. However, when this drug is given to young children, metaphyseal dysplasia and abnormalities of linear growth are frequently observed. To explore the notion that deferoximine mine interferes with endochondral growth by chelating zinc, we examined the effect of the drug on chondrocytes maintained in long-term culture. We found that deferoximine caused a dose-dependent inhibition of a wide range of functions including cell proliferation, protein synthesis (and possibly under-hydroxylation of type X collagen), and mineral deposition. Directly relevant to the mineralization process was the observation that the drug dramatically lowered the activity of alkaline phosphatase, a zinc-requiring enzyme. To test the hypothesis that enzyme inhibition was due to chelation of zinc by deferoximine, the cell culture medium was supplemented with excess zinc. However, this treatment did not overcome the deferoximine-dependent change in enzyme activity. We next examined the possibility that deferoximine, in the presence of ascorbate, could form a free radical system that would serve to inactivate the enzyme. Using alkaline phosphatase extracted from chick cartilage, we noted that the activity of the phosphatase was markedly reduced in the presence of deferoximine and ascorbate. These effects were consistant with the notion that deferoximine and ascorbate can act as a prooxidant couple. This conclusion was confirmed when we measured the oxidative activities of the system using nitroblue tetrazolium and cytochrome c. Indeed, we noted that deferoximine markedly activates the autocatalytic oxidation of ascorbate. We next investigated the possibility that the change in alkaline phosphatase activity was due to the formation of reactive oxygen radicals. Though oxygen radical scavengers and disproportionating agents did not change the activity of the enzyme, α-tocopherol provided complete protection. In conclusion, the deferoximine-ascorbate couple inactivates chondrocyte alkaline phosphatase probably by generation of free radicals. As free radicals can damage cartilage as well as other tissues, clinical regimens that are directed at elevating ascorbate levels in thalassemia need to be carefully reviewed.",
keywords = "Alkaline phosphatase, Ascorbate, Chondrocytes, Deferoximine, Free radicals, Mineralization, Thalassemia",
author = "M. Hatori and J. Sparkman and Cristina Teixeira and M. Grynpas and Jeanne Nervina and N. Olivieri and Shapiro, {I. M.}",
year = "1995",
month = "9",
doi = "10.1007/BF00310264",
language = "English (US)",
volume = "57",
pages = "229--236",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Effects of deferoximine on chondrocyte alkaline phosphatase activity

T2 - Proxidant role of deferoximine in thalassemia

AU - Hatori, M.

AU - Sparkman, J.

AU - Teixeira, Cristina

AU - Grynpas, M.

AU - Nervina, Jeanne

AU - Olivieri, N.

AU - Shapiro, I. M.

PY - 1995/9

Y1 - 1995/9

N2 - The homozygous form of β-thalassemia, the most common single gene disorder, is treated by red cell transfusion therapy. Following transfusion, the chelator, deferoximine, is administered to patients to remove excess iron. However, when this drug is given to young children, metaphyseal dysplasia and abnormalities of linear growth are frequently observed. To explore the notion that deferoximine mine interferes with endochondral growth by chelating zinc, we examined the effect of the drug on chondrocytes maintained in long-term culture. We found that deferoximine caused a dose-dependent inhibition of a wide range of functions including cell proliferation, protein synthesis (and possibly under-hydroxylation of type X collagen), and mineral deposition. Directly relevant to the mineralization process was the observation that the drug dramatically lowered the activity of alkaline phosphatase, a zinc-requiring enzyme. To test the hypothesis that enzyme inhibition was due to chelation of zinc by deferoximine, the cell culture medium was supplemented with excess zinc. However, this treatment did not overcome the deferoximine-dependent change in enzyme activity. We next examined the possibility that deferoximine, in the presence of ascorbate, could form a free radical system that would serve to inactivate the enzyme. Using alkaline phosphatase extracted from chick cartilage, we noted that the activity of the phosphatase was markedly reduced in the presence of deferoximine and ascorbate. These effects were consistant with the notion that deferoximine and ascorbate can act as a prooxidant couple. This conclusion was confirmed when we measured the oxidative activities of the system using nitroblue tetrazolium and cytochrome c. Indeed, we noted that deferoximine markedly activates the autocatalytic oxidation of ascorbate. We next investigated the possibility that the change in alkaline phosphatase activity was due to the formation of reactive oxygen radicals. Though oxygen radical scavengers and disproportionating agents did not change the activity of the enzyme, α-tocopherol provided complete protection. In conclusion, the deferoximine-ascorbate couple inactivates chondrocyte alkaline phosphatase probably by generation of free radicals. As free radicals can damage cartilage as well as other tissues, clinical regimens that are directed at elevating ascorbate levels in thalassemia need to be carefully reviewed.

AB - The homozygous form of β-thalassemia, the most common single gene disorder, is treated by red cell transfusion therapy. Following transfusion, the chelator, deferoximine, is administered to patients to remove excess iron. However, when this drug is given to young children, metaphyseal dysplasia and abnormalities of linear growth are frequently observed. To explore the notion that deferoximine mine interferes with endochondral growth by chelating zinc, we examined the effect of the drug on chondrocytes maintained in long-term culture. We found that deferoximine caused a dose-dependent inhibition of a wide range of functions including cell proliferation, protein synthesis (and possibly under-hydroxylation of type X collagen), and mineral deposition. Directly relevant to the mineralization process was the observation that the drug dramatically lowered the activity of alkaline phosphatase, a zinc-requiring enzyme. To test the hypothesis that enzyme inhibition was due to chelation of zinc by deferoximine, the cell culture medium was supplemented with excess zinc. However, this treatment did not overcome the deferoximine-dependent change in enzyme activity. We next examined the possibility that deferoximine, in the presence of ascorbate, could form a free radical system that would serve to inactivate the enzyme. Using alkaline phosphatase extracted from chick cartilage, we noted that the activity of the phosphatase was markedly reduced in the presence of deferoximine and ascorbate. These effects were consistant with the notion that deferoximine and ascorbate can act as a prooxidant couple. This conclusion was confirmed when we measured the oxidative activities of the system using nitroblue tetrazolium and cytochrome c. Indeed, we noted that deferoximine markedly activates the autocatalytic oxidation of ascorbate. We next investigated the possibility that the change in alkaline phosphatase activity was due to the formation of reactive oxygen radicals. Though oxygen radical scavengers and disproportionating agents did not change the activity of the enzyme, α-tocopherol provided complete protection. In conclusion, the deferoximine-ascorbate couple inactivates chondrocyte alkaline phosphatase probably by generation of free radicals. As free radicals can damage cartilage as well as other tissues, clinical regimens that are directed at elevating ascorbate levels in thalassemia need to be carefully reviewed.

KW - Alkaline phosphatase

KW - Ascorbate

KW - Chondrocytes

KW - Deferoximine

KW - Free radicals

KW - Mineralization

KW - Thalassemia

UR - http://www.scopus.com/inward/record.url?scp=0029076052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029076052&partnerID=8YFLogxK

U2 - 10.1007/BF00310264

DO - 10.1007/BF00310264

M3 - Article

VL - 57

SP - 229

EP - 236

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 3

ER -